Monographie - Netilmicin sulfate

Netilmicin sulfate

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Bactob	India
Beltob	India
Bramicil	Olaszország
Brulamycin	Magyarország
Eltol	India
Fytobra	India
Gernebcin	Németország
Komitub	India
Nebcin	Ausztrália, Egyesült Arab Emírségek, Egyiptom, Görögország, Nagy-Britannia, Szaúd-Arábiában, új-Zéland
Nebcina	Dánia, Marokkó, Norvégia, Svédország
Nebcine	Marokkó
Nebicina	Olaszország
Netilyn	Finnország, Svédország
Netromicina	Portugália
Netromicine	Franciaország
Netromycine	Görögország, Lengyelország, Orosz, Törökország
Nettacin	Olaszország
Obracin	Belgium, Hollandia, Luxemburg, Svájc
Tobra	Németország
Tobra Alex	Egyiptom
Tobra Day	új-Zéland
Tobra Gobens	Spanyolország
Tobracin	Egyiptom
Tobradistin	Spanyolország
Tobramicina	Olaszország, Portugália, Spanyolország, Venezuela
Tobramina	Brazília
Tobramycin	Amerikai Egyesült Államok, Ausztrália, Írország, Kanada, Nagy-Britannia, Németország, Norvégia, Szaúd-Arábiában
Tobramycine	Belgium, Hollandia, Kanada, Luxemburg
Tobrasix	Ausztria
Tobrazid	Németország
Tomycin	Finnország
Zetamicin	Olaszország

Irodalom : Netilmicin sulfate

	Type	Publikáció
3	Napló	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Napló	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
84	Napló	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Napló	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Napló	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Napló	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Napló	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
289	Napló	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
299	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Napló	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Napló	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
335	Napló	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
367	Napló	Thompson DF, Allen LV, Desai SR, Rao PS. Compatibility of furosemide with aminoglycoside admixtures. Am J Hosp Pharm 1985 ; 42: 116-119.
421	Napló	Foley PT, Bosso JA, Bair JN, Townsend RJ. Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures. Am J Hosp Pharm 1985 ; 42: 839-843.
492	Napló	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
905	Napló	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Napló	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
958	Napló	Vervloet E, Lammers J, Tan LSL, Van Mourik CH, Rots M. Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion. Ann Pharmacotherapy 1990 ; 24: 440-442.
999	Napló	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1022	Napló	Hutchinson SMW. Heparin and aminoglycosides instability. Drug Intell Clin Pharm 1986 ; 20: 886.
1035	Napló	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1200	Napló	Chaudry IA, Bruey KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742.
1236	Napló	Kuhn RJ, Nahata MC. Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline. Am J Hosp Pharm 1986 ; 43: 1241-1242.
1410	Napló	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Napló	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1754	Napló	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1925	Napló	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1929	Napló	Rigge DC, Jones MF. Shelf lives of aseptically prepared medicines - stability of netilmicin injection in polypropylene syringes. J Pharm Biomed Anal 2004 ; 35: 1251-1256.
2296	Laboratórium	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
3522	Laboratórium	Flucloxacillin - Summary of Product Characteristics. Actavis 2013
3523	Laboratórium	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3526	Laboratórium	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3527	Laboratórium	Amoxicillin (Amoxil®) – Summary of Product Characteristics Glaxo Smith Kline 2018
3540	Laboratórium	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3543	Laboratórium	Ceftazidime – Summary of Product Characteristics Wockhardt 2013
3544	Laboratórium	Cefoperazone (Cefobid®) - Summary of Product Characteristics Pfizer 2006
3545	Laboratórium	Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009
3546	Laboratórium	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3548	Laboratórium	Cefepime (Maxipime®) - Summary of Product caracteristics. Bristol Myers Squibb 2007
3578	Laboratórium	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3586	Laboratórium	Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit Actavis France 2010
3587	Laboratórium	Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics GlaxoSmithKline 2014
3594	Laboratórium	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3644	Laboratórium	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3656	Laboratórium	Teicoplanine (Targocid®) - Résumé des caractéristiques du produit Sanofi Aventis France 2014
3674	Laboratórium	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3687	Laboratórium	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3883	Laboratórium	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016